Company: INDP
Filing Date: 2025-02-12
Form Type: S-1
Source: 0001493152-25-006068
Chunk: 171

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-02-12
Form: S-1
Chunk 171
---
 reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The most significant estimates relate to the determination of the fair value of stock-based compensation and the determination of period-end obligations to certain contract research organizations. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and adjusts when facts and circumstances dictate. These estimates are based on information available as of the date of the condensed consolidated financial statements; therefore, actual results could differ from those estimates.

Loss per share

Loss per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is based upon the weighted average number of shares of common stock and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which are included under the treasury stock method when dilutive.

The following number of stock options and warrants were excluded from the calculation of diluted loss per share because their effect would have been anti-dilutive for the periods presented (share data):

SCHEDULE OF ANTI-DILUTIVE SECURITIES

|                           |     |   Weighted average |           |     |      |           |     |                   |           |     |      |           |
|                           |     | Three months ended |           |     |      |           |     | Nine months ended |           |     |      |           |
|                           |     |       September 30 |           |     |      |           |     |      September 30 |           |     |      |           |
|                           |     |               2024 |           |     | 2023 |           |     |              2024 |           |     | 2023 |           |
| Outstanding stock options |     |                    | 2,487,849 |     |      | 2,034,562 |     |                   | 2,408,456 |     |      | 1,955,182 |
| Warrants                  |     |                    | 4,048,188 |     |      | 3,090,787 |     |                   | 3,409,921 |     |      | 3,090,787 |

| F-21 |

Research and development expenses

Research and development expenses include costs directly attributable to the conduct of research and development programs, including